Haley F Stephens, PHD | |
1204 W Main St, Charlottesville, VA 22903-2824 | |
(434) 924-0123 | |
(434) 243-3300 |
Full Name | Haley F Stephens |
---|---|
Gender | Female |
Speciality | Psychologist - Clinical |
Location | 1204 W Main St, Charlottesville, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275017147 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2080P0006X | Pediatrics - Developmental - Behavioral Pediatrics | 0810006053 (Virginia) | Secondary |
103TC0700X | Psychologist - Clinical | 0810006053 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Haley F Stephens, PHD Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Haley F Stephens, PHD 1204 W Main St, Charlottesville, VA 22903-2824 Ph: (434) 924-0123 |
News Archive
The research group of Dr. Fran-ois Robert, a researcher at the Institut de recherches cliniques de Montr-al (IRCM), in collaboration with the team of Dr. Daniel Durocher (Samuel Lunenfeld Research Institute and University of Toronto) accomplished a technical breakthrough: they mapped all the fragile sites of a living organism, the budding yeast Saccharomyces cerevisiae. The method used by the researchers can be applied to humans. This study has been published online today in the scientific journal Nature Structural and Molecular Biology.
Researchers have discovered a protein they believe would help make vaccinations more effective and provide protection from other diseases such as cancer.
Transmissible spongiform encephalopathy or prion disease is triggered by the conversion from cellular prion protein to pathogenic prion protein.
orest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced positive top-line results from ACCORD COPD I, a three-month Phase III study comparing aclidinium 200µg and 400µg BID versus placebo.
› Verified 7 days ago